Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis

Details for Australian Patent Application No. 2003286467 (hide)

International Classifications

Event Publications

1 April 2004 Complete Application Filed

Priority application(s): 60/475,762 03.06.03 US; 60/418,972 15.10.02 US; 60/499,048 29.08.03 US; 60/462,014 10.04.03 US

10 June 2004 Application Open to Public Inspection

Published as AU-B-2003286467

21 June 2007 Change of Name(s) of Applicant(s), Section 104

Protien Design Labs, Inc. The name of the applicant has been changed to PDL BioPharma, Inc.

1 October 2009 Application Accepted

Published as AU-B-2003286467

22 October 2009 Assignment before Grant

PDL BioPharma, Inc. The application has been assigned to Facet Biotech Corporation 2004

28 January 2010 Standard Patent Sealed

26 May 2011 Alteration of Name

The name of the patentee has been altered to Abbott Biotherapeutics Corp. 2004

Legal

The information provided by the Site not in the nature of legal or other professional advice. The information provided by the Site is derived from third parties and may contain errors. You must make your own enquiries and seek independent advice from the relevant industry professionals before acting or relying on any information contained herein. Check the above data against the Australian Patent Office AUSPAT database.